SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (3267)9/30/2002 1:02:28 PM
From: Qualified Opinion  Read Replies (2) | Respond to of 10345
 
The 56 million shares sold short as of 9/13/2002 had a major impact on the stock price.



To: Icebrg who wrote (3267)9/30/2002 1:09:07 PM
From: scaram(o)uche  Read Replies (2) | Respond to of 10345
 
>> Each and every of these arrangements can be defended on its own merits. <<

I agree, with the exception of risk sharing. It still wouldn't be disclosed, if not for Enron, Eisinger and Schmuck. As time passed, the price for buying back royalties would have increased.

No amount of "it turned out OK" will temper my resentment.



To: Icebrg who wrote (3267)9/30/2002 1:47:31 PM
From: William Partmann  Respond to of 10345
 
Ice, well said, bravo.eom.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News